ABL Bio, Immune Checkpoint Inhibitor Theme Rises 5.26% Up

On the 19th, the immuno-oncology theme rose 3.07% compared to the previous day, showing strength, while ABL Bio, which is attracting attention as a related stock, surged 5.26% compared to the previous day.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme

According to provisional data compiled at 12:41, foreign investors have been buying 32,600 shares of ABL Bio, indicating a large net purchase by foreigners.

[Table] Net Trading Volume of Foreigners and Institutions (Unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, ABL Bio’s quant financial score is 5.42 points, ranking 18th in the immuno-oncology theme. This can be interpreted as ABL Bio having relatively low investment attractiveness from a financial perspective. On the other hand, Dong-A ST ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top Stocks by Financial Score within the Theme

※ The quant financial score is the result of the robo algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.